|
1
|
Roth CL, Elfers CT, Figlewicz DP, Melhorn
SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE and Kowdley KV:
Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty
liver disease and increases hepatic resistin and Toll-like receptor
activation. Hepatology. 55:1103–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan JG: Epidemiology of alcoholic and
nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol.
28 Suppl 1:S11–S17. 2013. View Article : Google Scholar
|
|
3
|
Fan JG and Zeng MD: Fatty liver disease.
Version 2. Beijing: People's Medical Publishing House 20; 2013
|
|
4
|
Farrell GC, McCullough AJ and Day CP:
Non-Alcoholic Fatty Liver Disease: A Practical Guide.
Wiley-Blackwell; Oxford: pp. 2162013
|
|
5
|
Loomba R, Sirlin CB, Schwimmer JB and
Lavine JE: Advances in pediatric nonalcoholic fatty liver disease.
Hepatology. 50:1282–1293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gorrell MD: Dipeptidyl peptidase IV and
related enzymes in cell biology and liver disorders. Clin Sci
(Lond). 108:277–292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fimeisz G, Varga T, Lengyel G, Fehér J,
Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K and Somogyi A:
Seram dipeptidyl peptidase-4 activity in insulin resistant patients
with nonalcoholic fatty liver disease: A novel liver disease
biomarker. PLoS One. 5:e122262010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ragab D, Laird M, Duffy D, Casrouge A,
Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR,
et al: CXCL10 antagonism and plasma sDPPIV correlate with
increasing liver disease in chronin HCV genotype 4 infected
patients. Cytokine. 63:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chielle Ottobelli E, de Souza WM, da Silva
TP, Moresco RN and Moretto MB: Adipocytokines, inflammatory and
oxidative stress markers of clinical relevance altered in young
overweight/obese subjects. Clin Biochem. 49:548–553. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Machado MV, Kruger L, Jewell ML,
Michelotti GA, Pereira Tde A, Xie G, Moylan CA and Diehl AM:
Vitamin B5 and N-acetylcysteine in nonalcoholic steatohepatitis: A
preclinical study in a dietary mouse model. Dig Dis Sci.
61:137–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qu QL, Zhang YG, Yang LZ and Sun L:
Intraperitoneal chemotherapy with mitomycin C bound to activated
carbon nanoparticles for nude mice bearing human gastric carcinoma.
Zhonghua Zhong Liu Za Zhi. 28:257–260. 2006.(In Chinese).
PubMed/NCBI
|
|
12
|
Wang FG, Zhuang RX, Xi JJ, Fang HY and Gao
JQ: Preparation and distribution in mice of acetylcysteine
nanoparticles. Zhongguo Yiyao Gongye Zazhi. 43:572–576. 2012.(In
Chinese).
|
|
13
|
Wang FG, Shen YQ, Zhuang RX, Xi JJ and
Fang HY: Study on preparation of acetylcysteine nanoparticles.
Strait Pharmaceut J. 25:15–17. 2013.
|
|
14
|
Jia L, Wang J, Shi JP, Wang F, Gang H, Zhu
M and Lou G: The effect of N-acetylcysteine nano-carbon on
anti-oxidative capacity in non-alcoholic steatohepatitis rats.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 28:4–6. 2014.(In
Chinese).
|
|
15
|
Fang HY, Zhang RX, Xi JJ, Sun JJ, Shao YD,
Si ZZ, Pan XW and Wang FG: Role of treatment on liver fibrosis of
activated carbon N-acetylcysteine microcapsule. Zhong Guo Lin
Chuang Yao Li Xue Yu Zhi Liao Xue Bian Ji Bu. 20:976–980. 2015.(In
Chinese).
|
|
16
|
Pei Z, Li X, Longenecker K, von Geldern
TW, Wiedeman PE, Lubben TH, Zinker BA, Stewart K, Ballaron SJ,
Stashko MA, et al: Discovery, structure-activity relationship, and
pharmacological evaluation of
(5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as
potent dipeptidyl peptidase IV Inhibitors. J Med Chem.
49:3520–3535. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Soslow RA, Dannenberg AJ, Rush D, Woerner
BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human
pulmonary, colonic, and mammary tumors. Cancer. 89:2637–2645. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lavine JE and Schwimmer JB: Nonalcoholic
fatty liver disease in the pediatric population. Clin Liver Dis.
8(549–558): viii–ix. 2004.
|
|
19
|
Fraser A, Longnecker MP and Lawlor DA:
Prevalence of elevated alanine aminotrasferase among US adolescents
and associated factors: NHANES 1999–2004. Gastroenterology.
133:1814–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwimmer JB, Deutsch R, Kahen T, Lavine
JE, Stanley C and Behling C: Prevalence of fatty liver in children
and adolescents. Pediatric. 118:1388–1393. 2006. View Article : Google Scholar
|
|
21
|
Kohli R, Boyd T, Lake K, Dietrich K,
Nicholas L, Balistreri WF, Ebach D, Shashidhar H and Xanthakos SA:
Rapid progression of NASH in childhood. J Pediatr Gastroenterol
Nutr. 50:453–456. 2010.PubMed/NCBI
|
|
22
|
Holterman A, Gurria J, Tanpure S and
DiSomma N: Nonalcoholic fatty liver disease and bariatric surgery
in adolescents. Semin Pediatr Surg. 23:49–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alterio A, Alisi A, Liccardo D and Nobili
V: Non-alcoholic fatty liver and metabolic syndrome in children: A
vicious circle. Horm Res Paediatr. 82:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ozhan B, Ersoy B, Kiremitci S, Ozkol M and
Taneli F: Insulin sensitivity indices: Fasting versus
glucose-stimulated indices in pediatric non-alcoholic fatty liver
disease. Eur Rev Med Pharmacol Sci. 19:3450–3458. 2015.PubMed/NCBI
|
|
25
|
Anderson EL, Howe LD, Jones HE, Higgins
JP, Lawlor DA and Fraser A: The prevalence of non-alcoholic fatty
liver disease in children and adolescents: A systematic review and
meta-analysis. PLoS One. 10:e01409082015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jogo R, Ness AR, Emmett P, Mattocks C,
Jones L and Riddoch CJ: Obesogenic diet and physical activity:
Independent or associated behaviours in adolescents? Public Health
Nutr. 13:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Monteiro PA, Antunes Bde M, Silveira LS,
Christofaro DG, Fernandes RA and Junior Freitas IF: Body
composition variables as predictors of NAFLD by ultrasound in obese
children and adolescents. BMC Pediatr. 14:252014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manco M, Bedogni G, Marcellini M, Devito
R, Ciampalini P, Sartorelli MR, Comparcola D, Piemonte F and Nobili
V: Waist circumference correlates with liver fibrosis in children
with non-alcoholic steatohepatitis. Gut. 57:1283–1287. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schwimmer JB, Celedon MA, Lavine JE, Salem
R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A,
Middleton MS and Sirlin CB: Heritability of nonalcoholic fatty
liver disease. Gastroenterology. 136:1585–1592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alisi A and Nobili V: Non-alcoholic fatty
liver disease in children now: Lifestyle changes and pharmacologic
treatments. Nutrition. 28:722–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Black LJ, Jacoby P, She Ping-Delfos WC,
Mori TA, Beilin LJ, Olynyk JK, Ayonrinde OT, Huang RC, Holt PG,
Hart PH, et al: Low serum 25-hydroxyvitamin D concentrations
associate with non-alcoholic fatty liver disease in adolescents
independent of adiposity. J Gastroenterol Hepatol. 29:1215–1222.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abdel-Rahman SM, Amidon GL, Kaul A,
Lukacova V, Vinks AA and Knipp GT: Summary of the national
institute of child health and human development-best
pharmaceuticals for children act pediatric formulation initiatives
workshop-pediatric biopharmaceutics classification system working
group. Clin Ther. 11:S11–S24. 2012. View Article : Google Scholar
|
|
33
|
Ma LX, Liu X, Yan GQ, et al: Problems and
thoughts on children drug use. Chin Hospitals. 16:45–46. 2012.
|
|
34
|
Hu N: Present situation and development
strategy of paediatric formulations. Med Sci. 1:2392015.
|
|
35
|
Drucker DJ and Nauck MA: The incretin
system: Glucagons-like peptide-l receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diahetes. Lancet. 368:1696–1705.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holst JJ: Glucagon-like peptide-1: From
extract to agent. The claude bernard lecture, 2005. Diabetologia.
49:253–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Balaban YH, Korkusuz P, Simsek H, Gokcan
H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E and Tatar
G: Dipeptidyl peptidaseIV (DPPIV) in NASH patients. Ann Hepatol.
6:242–250. 2007.PubMed/NCBI
|
|
38
|
Han Q: The study of the relationship
between DPPIV and fatty liver disease inobese children and young
rats. Tianjin Med Uni. 5:2011.
|
|
39
|
Shirakawa J, Fujii H, Ohnuma K, Sato K,
Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, et al:
Diet-induced adipose tissue inflammation and liver steatosis are
prevented by DPP-4 inhibition in diabetic mice. Diabetes.
60:1246–1257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yilmaz Y, Yonal O, Deyneli O, Celikel CA,
Kalayci C and Duman DG: Effects of sitagliptin in diabetic patients
with nonalcoholic steatohepatitis. Acta Gastroenterol Belg.
75:240–244. 2012.PubMed/NCBI
|
